- Home
- EQX vs FOLD Comparison
EQX vs FOLD Comparison
Compare EQX & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- FOLD
- Stock Information
- Founded
- EQX 2007
- FOLD 2002
- Country
- EQX Canada
- FOLD United States
- Employees
- EQX N/A
- FOLD N/A
- Industry
- EQX Precious Metals
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- FOLD Health Care
- Exchange
- EQX Nasdaq
- FOLD Nasdaq
- Market Cap
- EQX 3.2B
- FOLD 2.9B
- IPO Year
- EQX N/A
- FOLD 2007
- Fundamental
- Price
- EQX $6.09
- FOLD $5.64
- Analyst Decision
- EQX
- FOLD Buy
- Analyst Count
- EQX 0
- FOLD 10
- Target Price
- EQX N/A
- FOLD $16.22
- AVG Volume (30 Days)
- EQX 16.2M
- FOLD 4.5M
- Earning Date
- EQX 08-06-2025
- FOLD 08-07-2025
- Dividend Yield
- EQX N/A
- FOLD N/A
- EPS Growth
- EQX N/A
- FOLD N/A
- EPS
- EQX 0.64
- FOLD N/A
- Revenue
- EQX $1,696,526,000.00
- FOLD $543,141,000.00
- Revenue This Year
- EQX $40.61
- FOLD $19.84
- Revenue Next Year
- EQX $14.56
- FOLD $23.18
- P/E Ratio
- EQX $9.55
- FOLD N/A
- Revenue Growth
- EQX 54.88
- FOLD 28.25
- 52 Week Low
- EQX $4.48
- FOLD $5.62
- 52 Week High
- EQX $7.45
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- EQX 37.94
- FOLD 33.65
- Support Level
- EQX $6.17
- FOLD $6.00
- Resistance Level
- EQX $6.74
- FOLD $6.22
- Average True Range (ATR)
- EQX 0.23
- FOLD 0.19
- MACD
- EQX -0.09
- FOLD -0.01
- Stochastic Oscillator
- EQX 3.90
- FOLD 2.70
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.